Marina A. Budkovaia

Marina A. Budkovaia

Auto-generated profile, based on publicly available information

Marina A. Budkovaia

Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Russian Rhinology
Verified
Journal Article
Open access
PDF file
SRSergey Ryazantsev
Sergey Ryazantsev
MBM. A. Budkovaya
M. A. Budkovaya
Medical article медицинская статья

16 November 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SRSergey Ryazantsev
Sergey Ryazantsev
MBM. A. Budkovaya
M. A. Budkovaya
EAE. S. Artemyeva
E. S. Artemyeva
NKN. N. Khamgushkeeva
N. N. Khamgushkeeva
Objective. This study was conducted to increase effectiveness of anti-relapse therapy of chronic rhinosinusitis with polyps to create a stable long-term remission in the long-term postoperative period.Patients and research methods. 60 patients with total spread of polyposis process in the nasal cavity and paranasal sinuses were examined. All patients underwent endoscopic polysinusotomy and 3 weeks after surgery, basic anti-relapse therapy of PRS in the form Of nasonex intranasal spray of 400 mcg/day for 6 months in combination with irrigation with isotonic salt solutions was prescribed. At the same time, 30 patients 1.5 months after polysinusotomy were additionally given a short course of systemic corticosteroid therapy with Methylprednisolone, starting at 20 mg/day in combination with Omeprazole at 20 mg /day for 14 days. Subjective assessment of the patients ‘condition was carried out by questionnaire, for objective diagnosis acoustic rhinometry and CT of the paranasal sinuses were used.Results. Simultaneous administration of a short course of corticosteroid therapy in combination with prolonged intranasal use of Nasonex spray in patients with nasal polyps in the postoperative period contributed to the most rapid subjective improvement of nasal breathing. The combined scheme in 27 (90%) subjects showed a statistically significant improvement in intra-nasal aerodynamics (p<0.05) 2 months after polysinusotomy according to the results of acoustic rhinometry, the average MPPS1 was 0.67 ± 0,04 cm2 before and after the decongestant test. In 13 patients (44,3%) who received only intranasal corticosteroids reactive edema from the nasal mucosa were more pronounced, which contributed to the formation of zones of pathological narrowing of the nasal flow and a decrease in МППС1 to 0.43 ± 0,04см2 to test with decongestant. 2 years after surgical treatment in patients undergoing a combined course of corticosteroid therapy in relation to patients receiving only monotherapy with intranasal corticosteroids, there was no recurrence of polyposis in 86.7% of cases (26 patients), against 66.7% (20 patients), receiving only intranasal corticosteroids.

18 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SRSergey Ryazantsev
Sergey Ryazantsev
MBM. A. Budkovaia
M. A. Budkovaia
SRS. A. Rebrova
S. A. Rebrova
СРС. B. Рязанцев
С. B. Рязанцев
Currently, allergic sensitization is considered as one of the key causes of the development of chronic inflammatory processes in the nasal cavity and paranasal sinuses. The choice of optimal drugs for the treatment of allergic rhinitis still remains a relevant, socially significant and interdisciplinary problem. The article analyzes the modern strategy for the treatment of allergic rhinitis and assesses the incidence of comorbid pathology associated with allergic sensitization in patients with this pathology. In accordance with the latest clinical guidelines, a discussion of a stepwise approach to the treatment of allergic rhinitis was carried out. Based on data from a number of studies, the advantages of prescribing intranasal corticosteroids (InGCS) and leukotriene receptor antagonists (ALR) in the treatment of allergic rhinitis, including when combined with bronchial asthma and chronic rhinosinusitis with nasal polyps, have been identified. Among the officially registered drugs for the basic treatment of allergic rhinitis, the characteristics of the original intranasal spray mometasone furoate and the leukotriene receptor blocker montelukast are described in detail. The discussion describes the possibilities of potentiating the effects of topical corticosteroids through combination with leukotriene receptor antagonists. A clinical example demonstrates the feasibility of using a combination of the intranasal corticosteroid Nasonex with the leukotriene receptor blocker Singulair to control the course of allergic rhinitis and chronic rhinosinusitis with nasal polyps and, as a consequence, prevent the development of remodeling of the respiratory tract mucosa in such patients. During a follow-up examination after 3 months of therapy, the patient noted a subjective improvement in general well-being, nasal breathing, sense of smell, normalization of sleep, and a significant decrease in nasal discharge. There is no need for decongestants, sneezing is not a concern, and there is no respiratory discomfort. The combined use of ALR and InGCS enhances the anti-inflammatory effect of therapy.

1 January 2022 in Russian Otorhinolaryngology
Verified
Journal Article
Closed access
AKA. A. Korneenkov
A. A. Korneenkov
POP. A. Ovchinnikov
P. A. Ovchinnikov
KHKrasnogorsk Vishnevsky Central Military Clinical Hospital
Krasnogorsk Vishnevsky Central Military Clinical Hospital
MRM. V. Rezvantsev
M. V. Rezvantsev
SASaint Petersburg Kirov Military Medical Academy
Saint Petersburg Kirov Military Medical Academy
MBM. A. Budkovaya
M. A. Budkovaya
Case-control studies are retrospective observational studies designed to determine the relationship between the outcome of interest and its potential cause. This study design has known disadvantages: possible bias in the results, selection bias in the control group, etc. In order to avoid inconsistency between the study and control groups and thus underestimating of the possible influence of intervening factors (confounder), a whole class of methods is used to ensure that case-control matching pairs are selected and matched. Objective. To discuss and demonstrate the possibility of forming groups of research subjects (impact and control) on the basis of matching variables using the optimal matching procedure and compare the results of paired and unpaired analysis. Materials and methods. The baseline data were the results of a cross-sectional study of the impact of pandemic COVID-19 on health worker behavior. An example algorithm was used to assess the impact of awareness of different aspects of SARS-CoV-2 on health professionals. The processing was done in the R software environment. Discussion. The present study had two objectives: to demonstrate a method for optimal matching of case-control pairs for specific data and to estimate the effect of certain factors on the outcome of interest. Using this method allows for maximum consistency between study and control groups on selected matching variables. This tool simplifies and automates data preparation for subsequent analysis when case and potential control data are presented in a single dataset. Thus, the example shows that with different values of the number of controls per case indicator the point and interval estimate of the odds ratio varies slightly and indicates a statistically insignificant association between the need for more information and the forced use of leave by the health professional due to various concerns about the impact of COVID-19.

1 January 2025 in Russian Otorhinolaryngology
Verified
Journal Article
Closed access
SRS. A. Rebrova
S. A. Rebrova
MBM. A. Budkovaya
M. A. Budkovaya
SRSergey Ryazantsev
Sergey Ryazantsev
Аbstract. Introduction. Hypereosinophilia, often transient, is observed in patients with rhinosinusitis with nasal polyps (RSwNP) during dupilumab therapy. However, there are reports of hypereosinophilia leading to serious clinical manifestations. Objective. To evaluate the impact of hypereosinophilia during dupilumab treatment on the clinical outcome of patients with RSwNP in real-life clinical practice. Research methods. 176 patients over 18 years of age receiving dupilumab 300 mg subcutaneously once every 2 weeks for severe RSwNP were observed. Among these patients, a study group was identified that included patients who had an increase in the level of peripheral blood eosinophils of more than 1,500 cells per μL during the use of biological therapy. The clinical outcomes of treatment were assessed based on the dynamics of changes in the main nasal symptoms, the SNOT-22 questionnaire, the asthma control test (AСT), and an analysis of the distribution of polyps in the nasal cavity using the Nasal Polyp Score (NPS) scale. Results. Among 176 patients, 9 (5.1%) patients had peripheral blood eosinophilia of 1,500 cells per μL and higher during treatment with dupilumab. At the start of therapy, the average level of eosinophils in the peripheral blood was 450 cells per μL. In the fourth month from the start of treatment with dupilumab, a significant increase in the eosinophil level to 1,980 cells was noted, and eosinophilia was not accompanied by clinical symptoms: asthma control did not worsen, and the clinical symptoms of RSwNP improved (a significant decrease in NPS scores, SNOT 22 test indicators). A decrease in the level of peripheral blood eosinophils to 515 cells per μL was observed by the 14th month of dupilumab therapy in 6 (66.7%) patients, and by the 18th month of therapy in 3 (33.3%) patients the eosinophil level returned almost to the initial level. Conclusion. The results of clinical studies indicate a favorable safety profile of T2 targeted biological therapy. Eosinophilia occurring during treatment with dupilumab is often not associated with clinical symptoms. In clinical practice, an individual approach to patients, a thorough assessment of possible adverse events, in particular, hypereosinophilia, and their relationship with treatment are necessary.

23 April 2024 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
MBM.A. Budkovaya
M.A. Budkovaya
SRSergey Ryazantsev
Sergey Ryazantsev
SRS.A. Rebrova
S.A. Rebrova
Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses. The described clinical observation emphasizes the need to develop a personalized approach to prescribing immunobiological therapy in patients with CRSwNP and a more detailed study of the criteria for a super-response to this treatment.